Cytori Ready to Seek EU Approval of ATI-0918 as Bioequivalent to Caelyx for Ovarian Cancer

Cytori Ready to Seek EU Approval of ATI-0918 as Bioequivalent to Caelyx for Ovarian Cancer
Cytori Therapeutics reports that their compound ATI-0918 is equivalent to Janssen’s Caelyx (doxorubicin) — a previously approved liposomal formulation of doxorubicin hydrochloride for the treatment of ovarian cancer. The data stems from a so-called bioequivalence study, in which ovarian cancer patients switched from Caelyx to ATI-0918 or vice versa. Cytori presented data from the study at

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *